R

Roquefort Therapeutics PLC
LSE:ROQ

Watchlist Manager
Roquefort Therapeutics PLC
LSE:ROQ
Watchlist
Price: 1.27 GBX -5.93%
Market Cap: 2m GBX

Net Margin
Roquefort Therapeutics PLC

0%
Current
-218%
Average
3.7%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
0%
=
Net Income
-971.8k
/
Revenue
0

Net Margin Across Competitors

No Stocks Found

Roquefort Therapeutics PLC
Glance View

Market Cap
2m GBX
Industry
N/A

Roquefort Therapeutics plc operates as an investment company. The firm is developing products through the pre-clinical phase. The firm operates through its subsidiary Lyramid Pty Ltd (Lyramid). Lyramid is a pre-clinical biotechnology company focused on developing first-in-class Midkine inhibiting ribonucleic acid (RNA) therapeutic drugs for the treatment of cancer, chronic inflammatory, and autoimmune disorders, as well as lung diseases such as COVID-19. Lyramid has identified the therapeutic potential of Midkine for a number of clinical indications of unmet needs. Lyramid also intends to develop its oligonucleotide, and potentially antibody, drugs through preclinical and early clinical development.

ROQ Intrinsic Value
Not Available
R
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
0%
=
Net Income
-971.8k
/
Revenue
0
What is the Net Margin of Roquefort Therapeutics PLC?

Based on Roquefort Therapeutics PLC's most recent financial statements, the company has Net Margin of 0%.

Back to Top